Discovery Labs to raise $25M
Warrington-PA based Discovery Laboratories is aiming to raise $25 million in a registered direct offering, selling 10,000,000 shares of its common stock to institutional investors for $2.50 per share. The closing of the offering is expected to take place on December 12, 2007. Discovery's lead product candidate, Surfaxin, received an approvable letter from the FDA for prevention of Respiratory Distress Syndrome in premature infants. The drug is also being developed for other neonatal and pediatric indications.
- check out this release for more
Related Articles:
Discovery Labs to explore "strategic alternatives." Report
Discovery Labs pulls marketing app for Surfaxin. Report
Discovery Labs shares sink on data demand. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
